Dyadic's Stock Jumps On COVID-19 Vaccine Development Pact In India

by Vandana Singh, Benzinga Editor

May 26, 2021 9:25 AM | 30 seconds read |

Dyadic International Inc DYAI has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate.
The company says that the vaccine can potentially provide protection against the emerging variants and can be manufactured affordably, at an enormous scale, using Dyadic's proprietary C1-cell protein production platform.
Dyadic will work with Syngene to develop a vaccine candidate to immunize people against current and future variants of the COVID-19 virus.
Price Action: DYAI shares are up 11.9% at $4.33 during the premarket session on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care Contracts General Briefs COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.